Effect of Soliman Auricular Allergy Treatment (SAAT) on IgE-mediated Reactions Due to Exposure to Mammalian Meat Oligosaccharide, Galactose-α-1,3-Galactose

Abstract

Allergy to galactose 1,3, α-galactose (alpha gal)—a natural cellular carbohydrate component of non-catarrhine primate mammalian muscle tissue—is a recognized and prevalent disorder. No effective treatment has been established beyond palliative and emergency treatment medications used for food allergies, in general. This tick-triggered illness can affect humans, not only through mammalian meat consumption, but via exposure to numerous food and non-food products containing alpha gal, as well as skin contact and inhalation of airborne particulates. The objective was to document with a statistically powerful cohort, the efficacy of the ear acupuncture procedure, Soliman Auricular Allergy Treatment (SAAT), in support of the neurological theory of allergy. SAAT procedures involved electrical detection of case-specific auricular acupuncture points within the ovoid region designated as Soliman Allergy Zone (SAZ). 3mm-long, semi-permanent, intradermal ear acupuncture needles were inserted as indicated—secured by surgical tape and medical adhesive to enable ongoing stimulation for 3 weeks. Participants removed the acupuncture needles at home. Patients reported diverse histories of typical allergic symptoms, ranging from mild gastrointestinal or pruritic symptoms to severe anaphylactic reactions, as well as atypical symptoms such as joint problems, fatigue, anxiety, and sleep dysfunction. Primary outcome was patients’ written attestation of restored ability to be exposed to alpha gal without allergic incident, or significant reduction. Among the initial 155 patients providing follow up data, 147 patients reported some degree of returned consumption of mammalian meat without allergic incident, or significant reduction in severity or frequency. The paradigm-shifting relevance of this preliminary investigation—successfully treating a globally-relevant and problematic arthropod vector-triggered allergy, cannot be overestimated. No prophylactic or supportive treatment for AGA has been previously reported. The response was of groundbreaking statistical significance; the success rate for this first wave of follow-up responding participants who completed the treatment was 94.8%.